Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-21
2011-06-21
McGarry, Seam (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07964572
ABSTRACT:
Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4935363 (1990-06-01), Brown et al.
patent: 4959309 (1990-09-01), Dattagupta et al.
patent: 5070010 (1991-12-01), Hsu
patent: 5212071 (1993-05-01), Fearon et al.
patent: 5244805 (1993-09-01), Miller
patent: 5252216 (1993-10-01), Folena-Wasserman et al.
patent: 5256642 (1993-10-01), Fearon et al.
patent: 5262564 (1993-11-01), Kun et al.
patent: 5270163 (1993-12-01), Gold et al.
patent: 5338671 (1994-08-01), Scalice et al.
patent: 5428149 (1995-06-01), Eaton et al.
patent: 5456909 (1995-10-01), Marsh, Jr. et al.
patent: 5459015 (1995-10-01), Janjic et al.
patent: 5472841 (1995-12-01), Jayasena et al.
patent: 5472939 (1995-12-01), Fearon et al.
patent: 5475096 (1995-12-01), Gold et al.
patent: 5476766 (1995-12-01), Gold et al.
patent: 5496938 (1996-03-01), Gold et al.
patent: 5503978 (1996-04-01), Schneider et al.
patent: 5527894 (1996-06-01), Gold et al.
patent: 5543293 (1996-08-01), Gold et al.
patent: 5567588 (1996-10-01), Gold et al.
patent: 5580737 (1996-12-01), Polisky et al.
patent: 5635615 (1997-06-01), Allen et al.
patent: 5637459 (1997-06-01), Burke et al.
patent: 5648214 (1997-07-01), Nieuwlandt et al.
patent: 5654151 (1997-08-01), Allen et al.
patent: 5660985 (1997-08-01), Pieken et al.
patent: 5668264 (1997-09-01), Janjic et al.
patent: 5672695 (1997-09-01), Eckstein et al.
patent: 5674685 (1997-10-01), Janjic et al.
patent: 5683867 (1997-11-01), Biesecker et al.
patent: 5698687 (1997-12-01), Eckstein et al.
patent: 5705337 (1998-01-01), Gold et al.
patent: 5707796 (1998-01-01), Gold et al.
patent: 5723323 (1998-03-01), Kauffman et al.
patent: 5723750 (1998-03-01), Stubbs et al.
patent: 5726017 (1998-03-01), Lochrie et al.
patent: 5763173 (1998-06-01), Gold et al.
patent: 5763177 (1998-06-01), Gold et al.
patent: 5789157 (1998-08-01), Jensen et al.
patent: 5817635 (1998-10-01), Eckstein et al.
patent: 5840858 (1998-11-01), Smith et al.
patent: 5856297 (1999-01-01), Fearon et al.
patent: 5858969 (1999-01-01), Marsh, Jr. et al.
patent: 5861254 (1999-01-01), Schneider et al.
patent: 5919455 (1999-07-01), Greenwald et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5958691 (1999-09-01), Pieken et al.
patent: 5981481 (1999-11-01), Fearon et al.
patent: 6011020 (2000-01-01), Gold et al.
patent: 6013443 (2000-01-01), Heilig et al.
patent: 6020130 (2000-02-01), Gold et al.
patent: 6051698 (2000-04-01), Janjic et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6057131 (2000-05-01), Marsh, Jr. et al.
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6140490 (2000-10-01), Biesecker et al.
patent: 6147204 (2000-11-01), Gold et al.
patent: 6169068 (2001-01-01), Levin et al.
patent: 6207816 (2001-03-01), Gold et al.
patent: 6229002 (2001-05-01), Janjic et al.
patent: 6251588 (2001-06-01), Shannon et al.
patent: 6278039 (2001-08-01), Johnson et al.
patent: 6316604 (2001-11-01), Fearon et al.
patent: 6355245 (2002-03-01), Evans et al.
patent: 6395888 (2002-05-01), Biesecker et al.
patent: 6566343 (2003-05-01), Biesecker et al.
patent: 6573299 (2003-06-01), Petrus
patent: 7538211 (2009-05-01), Benedict et al.
patent: 7579456 (2009-08-01), Benedict et al.
patent: 2004/0180360 (2004-09-01), Wilson et al.
patent: 2004/0197804 (2004-10-01), Keefe et al.
patent: 2004/0249130 (2004-12-01), Stanton et al.
patent: 2005/0037394 (2005-02-01), Keefe et al.
patent: 2005/0214308 (2005-09-01), Ashkenazi et al.
patent: 2006/0018871 (2006-01-01), Benedict et al.
patent: 2006/0030535 (2006-02-01), Healy et al.
patent: 2006/0079477 (2006-04-01), Biesecker et al.
patent: 2007/0048248 (2007-03-01), Benedict et al.
patent: 2007/0117112 (2007-05-01), Diener et al.
patent: 2009/0269356 (2009-10-01), Epstein et al.
patent: 592035 (1994-04-01), None
patent: 2 183 661 (1987-06-01), None
patent: 2222345 (2004-01-01), None
patent: WO 89/06694 (1989-07-01), None
patent: WO 91/14436 (1991-10-01), None
patent: WO 91/19813 (1991-12-01), None
patent: WO 92/05285 (1992-04-01), None
patent: WO 92/07065 (1992-04-01), None
patent: WO 92/14842 (1992-09-01), None
patent: WO 92/14843 (1992-09-01), None
patent: WO 95/07364 (1995-03-01), None
patent: WO 97/28178 (1997-08-01), None
patent: WO 97/42317 (1997-11-01), None
patent: WO 98/18480 (1998-05-01), None
patent: WO 99/41271 (1999-08-01), None
patent: WO 2006/050498 (2006-05-01), None
Pestourie et al. (2005) Biochimie 87:921-930.
Acton (1993) J. Biol. Chem. 268:3530.
Biesecker (1996) Molecular Immunology 33 Supl. 1: 86.
Eikelenboom et al. (1982) Acta Neuropathol. (Berl.) 57:239.
Ellington and Szostak, (May 1990) Abstract of Papers Presented at the 1990 Meeting on RNA Processing, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., p. 84.
Jiang et al. (1992) The Journal of Biological Chemistry, 267(35):25597-25601.
Joyce (1989) Gene 82:83.
Joyce et al. (1989) Nucleic Acids Research 17:711.
Kinzler et al. (1989) Nucleic Acids Research 17:3645.
Kramer et al. (1974) J. Mol. Biol. 89:719.
Levisohn (1968) Proc. Natl. Acad. Sci. USA 60:866.
Levisohn et al. (1969) Proc. Natl. Acad. Sci. USA 63:805.
Morgan (1995) Crit. Rev. Clin. Lab. Sci. 32:265.
Oliphant et al. (1986) Gene 44:177.
Oliphant et al. (1987) Methods in Enzymology 155:568.
Oliphant et al. (1988) Nucleic Acids Research 16:7673.
Oliphant et al. (1989) Mol. Cell. Biol. 9:2944.
Robertson et al. (Mar. 1990) Nature 344:467.
Rosenberg et al. (1988) J. Rheumatol. 15:1091.
Szostak (1988) Redesigning the Molecules of Life, (S.A. Benner Ed.) Springer-Verlag Berlin Heidelberg, pp. 87-113, Astructure and Activity of Ribozymes.
Thiesen et al. (1990) Nucleic Acids Research 18:3203.
Van Schravendijk et al. (1982) Mol. Immunol. 19:1179.
Biesecker et al. Derivation of RNA aptamer inhibitors of human C5 (Apr. 1998) Molecular Immunology 35(6-7):334 (abstract only).
Matis, Louis A. and Rollins, Scott A., “Complement-specific antibodies: Designing novel anti-inflammatories,” (1995) Nature Medicine, vol. 1, No. 8, pp. 839-842.
Patt, Anita et al., “Xanthine Oxidase-derived Hydrogen Peroxide Contributes to Ischemia Reperfusion-induced Edema in Gerbil Brains,” (1988) Journal of Clinical Investigation, vol. 81, pp. 1556-1562.
Pellas, T.C. and Wennogle, L.P., “C5a Receptor Antagonists,” (1999) Current Pharmaceutical Design, vol. 5, pp. 737-755 (Abstract).
Rinder, Christine S. et al., “Blockade of C5a and C5b-9 Generation Inhibits Leukocyte and Platelet Activation during Extracorporeal Circulation,” (1995) Journal of Clinical Investigation, vol. 96, pp. 1564-1572.
Wang, Yi et al., “Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease,” (1995) Proceedings of the National Academy of Sciences, vol. 92, pp. 8955-8959.
Acosta et al., “Molecular basis for a link between complement and the vascular complications of diabetes”, PNAS (2002) 97(10): 5450-5455.
Agrawal et al., “Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies”, Proc. Natl. Acad. Sci. USA (1997) 94: 2620-2625.
Agrawal et al., “Novel enzymatic and immunological responses to oligonucleotides”, Tox. Lett. (1995) 82/83: 431-434.
Ahmed et al., “Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure”, Invest. Ophthalmol. Vis. Sci. (2004) 45(4):1247-1254.
Albrecht et al., “C5a-Induced Gene Expression in Human Umbilical Vein Endotheilial Cells”, Am. J. Pathology (2004) 164(3): 849-859.
Allegretti et al., “Targeting C5a: Recent Advances in
Biesecker Gregory
Gold Larry
Gibbs Terra Cotta
Gilead Sciences, Inc.
McGarry Seam
Swanson & Bratschun L.L.C.
LandOfFree
High affinity nucleic acid ligands of complement system... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High affinity nucleic acid ligands of complement system..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High affinity nucleic acid ligands of complement system... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2743422